Quick Answer
PMV Pharmaceuticals, Inc. reported Operating Income Loss of -$86.21 million for the year ending 2025.
- PMV Pharmaceuticals, Inc. showed a decrease of -0.9% in Operating Income Loss from 2024 to 2025.
- This data is from PMV Pharmaceuticals, Inc.'s annual report (Form 10-K), filed with the SEC on March 6, 2026.
- XBRL data for this metric is available from 2018 to 2025 (8 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2019: -$6.44 million | Q1 2020: -$7.65 million | Q2 2020: -$8.09 million | Q3 2020: -$8.70 million | Q1 2021: -$11.67 million | Q2 2021: -$13.05 million | Q3 2021: -$15.10 million | Q1 2022: -$18.62 million | Q2 2022: -$17.89 million | Q3 2022: -$19.38 million | Q1 2023: -$21.48 million | Q2 2023: -$20.12 million | Q3 2023: -$19.63 million | Q1 2024: -$18.22 million | Q2 2024: -$20.17 million | Q3 2024: -$21.89 million | Q1 2025: -$21.56 million | Q2 2025: -$22.88 million | Q3 2025: -$22.52 million.
- Over the full 8 years of available data (2018 to 2025), PMV Pharmaceuticals, Inc.'s Operating Income Loss has declined by 356.3%.
- Historical annual values: Fiscal year 2025: -$86.21 million | Fiscal year 2024: -$85.45 million | Fiscal year 2023: -$80.13 million | Fiscal year 2022: -$77.04 million | Fiscal year 2021: -$58.29 million | Fiscal year 2020: -$34.94 million | Fiscal year 2019: -$26.64 million | Fiscal year 2018: -$18.89 million.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: